Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI) in a research note issued on Friday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Several other analysts also recently commented on the stock. Piper Sandler reaffirmed a “neutral” rating and set a $132.00 target price (up previously from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Needham & Company LLC restated a “hold” rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. Canaccord Genuity Group lowered Intra-Cellular Therapies from a “buy” rating to a “hold” rating and increased their target price for the stock from $119.00 to $132.00 in a research note on Friday, January 31st. Baird R W cut Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Finally, Mizuho lowered Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $140.00 to $132.00 in a report on Monday, February 24th. Ten equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $106.08.

Intra-Cellular Therapies Trading Up 0.0 %

Shares of NASDAQ ITCI opened at $131.75 on Friday. The company has a market capitalization of $14.01 billion, a P/E ratio of -151.44 and a beta of 0.69. Intra-Cellular Therapies has a 12 month low of $64.09 and a 12 month high of $131.79. The stock has a 50 day moving average of $129.00 and a 200-day moving average of $99.05.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. Analysts predict that Intra-Cellular Therapies will post -0.64 EPS for the current fiscal year.

Institutional Investors Weigh In On Intra-Cellular Therapies

Several institutional investors and hedge funds have recently bought and sold shares of ITCI. Cerity Partners LLC raised its position in shares of Intra-Cellular Therapies by 62.9% in the 3rd quarter. Cerity Partners LLC now owns 44,107 shares of the biopharmaceutical company’s stock valued at $3,227,000 after buying an additional 17,027 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in Intra-Cellular Therapies by 1.3% in the third quarter. The Manufacturers Life Insurance Company now owns 22,057 shares of the biopharmaceutical company’s stock valued at $1,614,000 after acquiring an additional 283 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Intra-Cellular Therapies by 13.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 22,522 shares of the biopharmaceutical company’s stock worth $1,648,000 after purchasing an additional 2,622 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Intra-Cellular Therapies by 3.6% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 323,208 shares of the biopharmaceutical company’s stock worth $23,649,000 after purchasing an additional 11,104 shares during the last quarter. Finally, Vestal Point Capital LP bought a new stake in Intra-Cellular Therapies during the third quarter worth $2,195,000. Institutional investors own 92.33% of the company’s stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.